2015: New Heart Failure Drug

On This Day in Health: April 15, 2015

On April 15, 2015, the U.S. Food and Drug Administration approved Corlanor, or ivabradine, to reduce the risk of hospitalization for worsening heart failure in a defined group of adults. The indication concerned stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction, normal sinus rhythm and an elevated resting heart rate. Patients also had to be taking a maximally tolerated beta blocker or have a contraindication to that treatment. The approval added an option directed at heart rate within a carefully specified clinical setting. It was not an authorization for every person with heart disease, nor did it replace the need for other established care.

Heart failure describes a condition in which the heart cannot meet the body’s needs adequately. In the population covered by the approval, the left ventricle’s pumping ability was substantially reduced. Ejection fraction measures the proportion of blood expelled from that chamber with each contraction; the original indication used a threshold of thirty-five percent or less. Resting heart rate and rhythm also mattered because ivabradine acts on the sinus node’s pacemaker activity. It inhibits the current involved in that activity and slows heart rate. These requirements show how a medicine’s mechanism helps determine eligibility. Similar symptoms can arise in patients whose rhythm or other circumstances make the same drug inappropriate.

The decision was supported by clinical evidence including the large randomized, placebo-controlled SHIFT trial. Participants received ivabradine or placebo alongside standard care. The study’s combined primary outcome involved hospitalization for worsening heart failure or cardiovascular death. The benefit reflected fewer hospitalizations for worsening heart failure; it did not demonstrate a favorable effect on the mortality component of that primary outcome. This distinction is central to describing the advance accurately. Avoiding hospitalization can be important to patients and health services, but it should not be translated automatically into a claim that the medicine proved people lived longer. The measured outcome and the approved purpose remained closely connected.

April 15 represents a targeted addition to the management of a chronic condition that can repeatedly disrupt daily life. The medicine’s use required attention to heart rate, rhythm, other treatments and adverse effects, including excessively slow heart rate and atrial fibrillation. The anniversary illustrates why clinical progress often depends on identifying a suitable subgroup rather than offering a single solution to everyone. It also highlights the value of precise outcome language. A reduction in hospital admissions is a concrete benefit with its own significance, even when a trial does not show a mortality advantage. The enduring milestone is a new, evidence-based option for selected patients, accompanied by the practical responsibility to apply the findings within the population and purpose actually studied.